During the past decade, Washington University School of Medicine Division of Oncology conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 6 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 3 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Washington University School of Medicine Division of Oncology" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Novartis Pharmaceuticals" with 4 trials sponsored, "Multiple Myeloma Research Consortium" with 2 trials sponsored, "NovoCure Ltd." with 2 trials sponsored and "PharmaEssentia" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Washington University School of Medicine Division of Oncology" #1 collaborator was "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator, "GOG Foundation" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Beth Israel Deaconess Medical Center" with 1 trials as a collaborator and "Brightech International" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Washington University School of Medicine Division of Oncology" are "Essential Thrombocythemia" (2 trials), "Multiple Myeloma" (2 trials), "Neoplasms" (2 trials), "Ovarian Cancer" (2 trials) and "Relapsed Refractory Multiple Myeloma" (2 trials). Many other conditions were trialed in "Washington University School of Medicine Division of Oncology" in a lesser frequency.

Most popular intervention types in "Washington University School of Medicine Division of Oncology" are "Drug" (22 trials), "Biological" (2 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (5 trials), "Cobimetinib" (3 trials), "Everolimus" (3 trials), "Paclitaxel" (3 trials) and "AEB071" (2 trials). Other intervention names were less common.

The vast majority of trials in "Washington University School of Medicine Division of Oncology" are 21 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Washington University School of Medicine Division of Oncology". undefined are not yet recruiting, 8 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Washington University School of Medicine Division of Oncology, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Washington University School of Medicine Division of Oncology, 11 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".